A Phase 4 interventional study of Omeprazole High dose and Omeprazole Low dose in Gastroduodenal Ulcer, Marginal Ulcer and Peptic Ulcer Hemorrhage, sponsored by Damascus Hospital. Withdrawn at 1 site in Syrian Arab Republic. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-07-10.
Sponsored by Damascus Hospital · Phase 4, Interventional, and Treatment
Evaluate the efficacy of Two different regimens of proton pump inhibitors High against Low in the management of acute peptic ulcer bleeding
Evaluate the efficacy of Two different regimens of proton pump inhibitors in the management of acute peptic ulcer bleeding First: loading dose 80 mg then 8mg/h iv continuous infusion for 3 days Second Loading dose 80 mg the 40 mg every 12 h for 3 days
193 studies on the registry are indexed under Peptic Ulcer; 31 are open to participants now.
Browse Peptic Ulcer studies →Damascus Hospital is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Omeprazole 80 mg loading dose,then 8mg/h IV continuous infusion for 3 days
Drug: Omeprazole High dose
Omeprazole 80 mg loading dose IV then 40 mg two times per day IV for 3 days
Drug: Omeprazole Low dose
High regimen of Proton Pump Inhibitors in treatment of bleeding ulcer 80 mg loading dose then 8 mg/h iv for 3 days
low regimen of Proton Pump Inhibitors in treatment bleeding ulcer 80 mg loading dose then 40 mg two times per day for 3 days
Mortality
Time frame: 1 month
Rebleeding
recurrent melena (black, tarry stool) or recurrent Hematemesis or coffee-ground emesis or recurrent hematochezia after begin treatment
Time frame: one month
Surgery
need for surgery
Time frame: one month
Length of hospital stay
Time frame: one month
Blood transfusions
number of transfusion blood unites during admission
Time frame: one month
Plan to share: Undecided
No publications or documents are linked to this record.
This study is withdrawn, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Damascus Hospital